2023
Optimizing Donor Chimerism Threshold for Next-Generation Sequencing Monitoring of Measurable Residual Disease Post-Allogeneic Stem Cell Transplantation for Myeloid Neoplasms
Puzo C, Tormey C, Rinder H, Siddon A. Optimizing Donor Chimerism Threshold for Next-Generation Sequencing Monitoring of Measurable Residual Disease Post-Allogeneic Stem Cell Transplantation for Myeloid Neoplasms. Transplantation And Cellular Therapy 2023, 29: 459.e1-459.e4. PMID: 37062510, DOI: 10.1016/j.jtct.2023.04.005.Peer-Reviewed Original ResearchConceptsAllogeneic stem cell transplantationStem cell transplantationDonor chimerismCell transplantationNGS testingPost allogeneic stem cell transplantationMeasurable residual diseaseNext-generation sequencingAcute myeloid leukemiaConditioning regimenRelated donorsMyelodysplastic syndromeResidual diseaseValidation cohortMyeloid leukemiaMyeloid neoplasmsNGS panelLogistic regressionPatientsChimerismSignificant predictorsCharacteristic curveTransplantationRegimenConservative threshold
2022
Autoimmune hemolytic anemias and paroxysmal nocturnal hemoglobinuria
Tormey C, Siddon A. Autoimmune hemolytic anemias and paroxysmal nocturnal hemoglobinuria. 2022, 346-363. DOI: 10.1002/9781119719809.ch31.ChaptersParoxysmal nocturnal hemoglobinuriaAutoimmune hemolytic anemiaHemolytic anemiaNocturnal hemoglobinuriaMainstay of therapyChoice of therapyDegree of anemiaBone marrow dysfunctionTypes of symptomsBlood transfusionCold autoantibodiesMarrow dysfunctionRBC destructionPNH patientsPrimary disorderSevere hemolysisRare typeAnemiaAutoantibodiesSingle disorderMedical issuesUnique entityPatientsTherapyHemoglobinuriaAutomated analysers underestimate atypical basophil count in myeloid neoplasms
Shah HP, Tormey CA, Siddon AJ. Automated analysers underestimate atypical basophil count in myeloid neoplasms. International Journal Of Laboratory Hematology 2022, 44: 831-836. PMID: 35609868, DOI: 10.1111/ijlh.13882.Peer-Reviewed Original ResearchConceptsMyeloid neoplasmsBasophil percentageBasophil countsMyeloproliferative neoplasmsManual differentialMyeloid disordersFlow cytometryTertiary care centerChronic myeloid leukemiaMyeloid neoplasms patientsControl patientsMyelodysplastic diseasesMean ageNeoplasm patientsControl subjectsCare centerMyeloid leukemiaPatientsNeoplasmsAtypical appearanceScatter propertiesMyeloid diseasesBasophilsDisorder diagnosisCytometry
2020
Criteria for Ordering Myeloid Neoplasm Next-Generation Sequencing to Optimize Personalized Patient Care and Cost
Gisriel S, Rinder H, Siddon A. Criteria for Ordering Myeloid Neoplasm Next-Generation Sequencing to Optimize Personalized Patient Care and Cost. Blood 2020, 136: 39-40. DOI: 10.1182/blood-2020-139035.Peer-Reviewed Original ResearchNext-generation sequencingNGS testingNGS testsAML/MDSEvidence-based indicationsPatients' emotional distressCancellation criteriaMedicaid Services reimbursementPersonalized patient careClinical suspicionPathologic diagnosisMedical recordsClinical indicationsClinical trialsChimerism statusUnnecessary testingMDS progressionPatient carePathogenic variantsMolecular findingsUnknown significancePatientsPathogenic mutationsService reimbursementMolecular diagnostic laboratoriesIsolated trisomy 11 in patients with acute myeloid leukemia – is the prognosis not as grim as previously thought?*
Bewersdorf JP, Shallis RM, Diadamo A, Gowda L, Podoltsev NA, Siddon A, Zeidan AM. Isolated trisomy 11 in patients with acute myeloid leukemia – is the prognosis not as grim as previously thought?*. Leukemia & Lymphoma 2020, 61: 2254-2257. PMID: 32338096, PMCID: PMC7485109, DOI: 10.1080/10428194.2020.1755858.Peer-Reviewed Original Research
2019
Red blood cell alloimmunization is associated with lower expression of FcγR1 on monocyte subsets in patients with sickle cell disease
Balbuena‐Merle R, Curtis SA, Devine L, Gibb DR, Karafin MS, Luckey CJ, Tormey CA, Siddon AJ, Roberts JD, Hendrickson JE. Red blood cell alloimmunization is associated with lower expression of FcγR1 on monocyte subsets in patients with sickle cell disease. Transfusion 2019, 59: 3219-3227. PMID: 31355970, PMCID: PMC7075520, DOI: 10.1111/trf.15463.Peer-Reviewed Original ResearchConceptsSickle cell diseaseMonocyte subsetsTotal monocytesCell diseaseComplications of SCDRed blood cell alloimmunizationRed blood cell alloantibodiesElectronic medical recordsTransfusion exposureSerum cytokinesIntermediate monocytesRBC alloantibodiesInflammatory milieuCD64 expressionClassical monocytesPeripheral bloodInflammatory functionsMedical recordsAntibody formationClinical significancePatientsMonocytesFlow cytometryLow expressionResponders
2018
Modified approach to fibrinogen replacement in the setting of dysfibrinogenaemia
Chandler JB, Siddon AJ, Bahel P, Torres R, Rinder HM, Tormey CA. Modified approach to fibrinogen replacement in the setting of dysfibrinogenaemia. Journal Of Clinical Pathology 2018, 72: 177. PMID: 30463936, DOI: 10.1136/jclinpath-2018-205438.Peer-Reviewed Original ResearchFalse-Positive Light Chain Clonal Restriction by Flow Cytometry in Patients Treated With Alemtuzumab
Chen PP, Tormey CA, Eisenbarth SC, Torres R, Richardson SS, Rinder HM, Smith BR, Siddon AJ. False-Positive Light Chain Clonal Restriction by Flow Cytometry in Patients Treated With Alemtuzumab. American Journal Of Clinical Pathology 2018, 151: 154-163. PMID: 30307483, DOI: 10.1093/ajcp/aqy129.Peer-Reviewed Original ResearchConceptsHealthy donor bloodAlemtuzumab treatmentDonor bloodBone marrowFlow cytometryLight chain restrictionT-cell prolymphocytic leukemiaB-cell neoplasmsLight chain clonalityFlow cytometry analysisAutoimmune diseasesHematologic malignanciesImmunophenotypic analysisChain restrictionAlemtuzumabT cellsB cellsProlymphocytic leukemiaImmunoglobulin G1PatientsMonoclonal antibodiesCytometry analysisSimilar findingsBloodClonal restrictionACUTE HYPOXEMIA DUE TO PULMONARY LEUKEMIC INFILTRATES IN A PATIENT WITH NEWLY DIAGNOSED T-CELL PRO-LYMPHOCYTIC LEUKEMIA
MAINARDI A, HILBERT J, BADER A, SIDDON A. ACUTE HYPOXEMIA DUE TO PULMONARY LEUKEMIC INFILTRATES IN A PATIENT WITH NEWLY DIAGNOSED T-CELL PRO-LYMPHOCYTIC LEUKEMIA. CHEST Journal 2018, 154: 414a. DOI: 10.1016/j.chest.2018.08.378.Peer-Reviewed Case Reports and Technical NotesBe careful of the masquerades: differentiating secondary myelodysplasia from myelodysplastic syndromes in clinical practice
Shallis RM, Xu ML, Podoltsev NA, Curtis SA, Considine BT, Khanna SR, Siddon AJ, Zeidan AM. Be careful of the masquerades: differentiating secondary myelodysplasia from myelodysplastic syndromes in clinical practice. Annals Of Hematology 2018, 97: 2333-2343. PMID: 30109425, DOI: 10.1007/s00277-018-3474-7.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMyelodysplastic syndromeSecondary myelodysplasiaSecondary causesAllogeneic hematopoietic cell transplantationDiagnosis of MDSRepresentative case seriesUnderlying myelodysplastic syndromeHematopoietic cell transplantationLack of efficacyHematologists/oncologistsMeticulous exclusionResultant cytopeniasIntensive chemotherapyCase seriesMorphologic reviewCell transplantationDiagnostic dilemmaSuch therapyMalignant processExpert hematopathologistsClinical practiceMyelodysplasiaCytogenetic abnormalitiesPatientsSpecialized physiciansHematopoietic Stem Cell Donor Selection and Graft-Versus-Host Disease
Siddon A, Tormey C. Hematopoietic Stem Cell Donor Selection and Graft-Versus-Host Disease. 2018, 105-117. DOI: 10.1007/978-3-319-89866-7_7.ChaptersCell transplantSide effectsHematopoietic progenitor cell transplantStem cell transplantMalignant hematological diseasesProgenitor cell transplantPotential side effectsStem cell sourceGraft-VersusHPC transplantHost diseaseABO compatibilityPotential complicationsDonor selectionHematological diseasesApheresis servicesPossible treatmentTransplantSevere disordersCell sourceDiseaseManagement optionsComplicationsPatientsTransplantation